BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20618793)

  • 1. Net clinical benefit: the art and science of jointly estimating benefits and risks of medical treatment.
    Towse A
    Value Health; 2010 Jun; 13 Suppl 1():S30-2. PubMed ID: 20618793
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness/efficacy difference too often ignored.
    Silverman E
    Manag Care; 2013 Jan; 22(1):36. PubMed ID: 23373138
    [No Abstract]   [Full Text] [Related]  

  • 3. Health technology assessment and comparative effectiveness in Sweden.
    Jonsson E
    Value Health; 2010 Jun; 13 Suppl 1():S6-7. PubMed ID: 20618795
    [No Abstract]   [Full Text] [Related]  

  • 4. Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?
    Hughes DA; Bayoumi AM; Pirmohamed M
    Clin Pharmacol Ther; 2007 Aug; 82(2):123-7. PubMed ID: 17632534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of research and value of development in early assessments of new medical technologies.
    Retèl VP; Grutters JP; van Harten WH; Joore MA
    Value Health; 2013; 16(5):720-8. PubMed ID: 23947964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'Health Economics' and the evolution of economic evaluation of health technologies.
    Hutton J
    Health Econ; 2012 Jan; 21(1):13-8. PubMed ID: 22147623
    [No Abstract]   [Full Text] [Related]  

  • 7. What can we really learn from observational studies?: the need for empirical assessment of methodology for active drug safety surveillance and comparative effectiveness research.
    Madigan D; Ryan P
    Epidemiology; 2011 Sep; 22(5):629-31. PubMed ID: 21811110
    [No Abstract]   [Full Text] [Related]  

  • 8. Multiple criteria decision analysis for health technology assessment.
    Thokala P; Duenas A
    Value Health; 2012 Dec; 15(8):1172-81. PubMed ID: 23244821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Values and evidence colliding: health technology assessment in child health.
    Ungar WJ; Prosser LA; Burnett HF
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):417-9. PubMed ID: 23977967
    [No Abstract]   [Full Text] [Related]  

  • 10. A framework for designing transgenic crops--science, safety and citizen's concerns.
    König A
    Nat Biotechnol; 2003 Nov; 21(11):1274-9. PubMed ID: 14595351
    [No Abstract]   [Full Text] [Related]  

  • 11. [Assessment of service life of sophisticated medical equipment].
    Toporkov AA
    Med Tekh; 2007; (3):26-33. PubMed ID: 17598479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality, innovation, and value for money: NICE and the British National Health Service.
    Pearson SD; Rawlins MD
    JAMA; 2005 Nov; 294(20):2618-22. PubMed ID: 16304076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technology assessment and cost-effectiveness analysis: misguided guidelines?
    Naylor CD; Williams JI; Basinski A; Goel V
    CMAJ; 1993 Mar; 148(6):921-4. PubMed ID: 8448706
    [No Abstract]   [Full Text] [Related]  

  • 14. Basic concepts and fundamental issues in technology assessment.
    Franklin C
    Intensive Care Med; 1993; 19(2):117-21. PubMed ID: 8486866
    [No Abstract]   [Full Text] [Related]  

  • 15. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Good pharmacovigilance practices: technology enabled.
    Nelson RC; Palsulich B; Gogolak V
    Drug Saf; 2002; 25(6):407-14. PubMed ID: 12071777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complementing the net benefit approach: a new framework for Bayesian cost-effectiveness analysis.
    Hernández MA; Vázquez-Polo FJ; González-Torre FJ; Bas EM
    Int J Technol Assess Health Care; 2009 Oct; 25(4):537-45. PubMed ID: 19845984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A framework to evaluate the cost-effectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer.
    Reed SD; Stewart SB; Scales CD; Moul JW
    Value Health; 2014 Jul; 17(5):545-54. PubMed ID: 25128047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Life-cycle management: a long-term challenge.
    Newman C
    Med Device Technol; 2003 Apr; 14(3):32-3. PubMed ID: 12789698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on technology assessment in dentistry.
    Antczak-Bouckoms A; Tulloch JF
    Curr Opin Dent; 1992 Jun; 2():10-4. PubMed ID: 1387819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.